首页> Journal of medicinal chemistry> Metabotropic glutamate receptor 5 negative allosteric modulators: discovery of 2-chloro-4-[1-(4-fluorophenyl)-2,5-dimethyl-1H-imidazol-4-ylethynyl]pyridine (basimglurant, RO4917523), a promising novel medicine for psychiatric diseases.

Metabotropic glutamate receptor 5 negative allosteric modulators: discovery of 2-chloro-4-[1-(4-fluorophenyl)-2,5-dimethyl-1H-imidazol-4-ylethynyl]pyridine (basimglurant, RO4917523), a promising novel medicine for psychiatric diseases.

导出 LinkOut

翻译打印收藏纠错

第一作者： Georg,Jaeschke

第一单位： Discovery Chemistry, Therapeutic Modalities, ‡Discovery Neuroscience, Neuroscience, Ophthalmology & Rare Diseases (NORD), §Communications, ∥Pharmaceutical Sciences, ⊥Molecular Design and Chemical Biology, Therapeutic Modalities, #Small Molecules Process Research and Synthesis, Therapeutic Modalities, ∞Infections Diseases, and ×Operations for Neuroscience, Ophthalmology, and Rare Diseases (NORD), Innovation Center Basel, Roche Pharmaceutical Research and Early Development , Grenzacherstrasse 124, CH-4070 Basel, Switzerland.

作者： Georg,Jaeschke ^[1] ; Sabine,Kolczewski ; Will,Spooren ; Eric,Vieira ; Nadia,Bitter-Stoll ; Patrick,Boissin ; Edilio,Borroni ; Bernd,Büttelmann ; Simona,Ceccarelli ; Nicole,Clemann ; Beatrice,David ; Christoph,Funk ; Wolfgang,Guba ; Anthony,Harrison ; Thomas,Hartung ; Michael,Honer ; Jörg,Huwyler ; Martin,Kuratli ; Urs,Niederhauser ; Axel,Pähler ; Jens-Uwe,Peters ; Ann,Petersen ; Eric,Prinssen ; Antonio,Ricci ; Daniel,Rueher ; Marianne,Rueher ; Manfred,Schneider ; Paul,Spurr ; Theodor,Stoll ; Daniel,Tännler ; Jürgen,Wichmann ; Richard H,Porter ; Joseph G,Wettstein ; Lothar,Lindemann

作者单位： Discovery Chemistry, Therapeutic Modalities, ‡Discovery Neuroscience, Neuroscience, Ophthalmology & Rare Diseases (NORD), §Communications, ∥Pharmaceutical Sciences, ⊥Molecular Design and Chemical Biology, Therapeutic Modalities, #Small Molecules Process Research and Synthesis, Therapeutic Modalities, ∞Infections Diseases, and ×Operations for Neuroscience, Ophthalmology, and Rare Diseases (NORD), Innovation Center Basel, Roche Pharmaceutical Research and Early Development , Grenzacherstrasse 124, CH-4070 Basel, Switzerland. ^[1]